(Q37599890)

21 August 2017

1 reference

title

Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression (English)

1 reference

21 August 2017

1 reference

ChEBI release 2020-05-28

Arif Khan

1

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

18

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1753-1764

1 reference

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Risk of mortality among depressed younger patients: a five-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

A 40-year perspective on the prevalence of depression: the Stirling County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Association between depression and mortality in older adults: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Is there a role for 5-HT1A agonists in the treatment of depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Gepirone Extended-Release in the Treatment of Adult Outpatients With Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Clinical Effects of the 5-HT1A Partial Agonists in Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Recent developments and current controversies in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Placebo response in studies of major depression: variable, substantial, and growing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903286396

10.1517/13543780903286396

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference